This article is a review of studies in which endotoxin has been administered to human subjects for experimental purposes. Data are presented in tabular form so the reader can better appreciate the objectives of individual studies. Although the original intention was to focus on the adverse events associated with these studies, unexpected serious adverse events rarely have been reported.
Wolff SMBiological effects of bacterial endotoxins in man. J Infect Dis1973; 128: S259—S264.
3.
Lowry SFHuman endotoxemia: a model for mechanistic insight and therapeutic targeting . Shock2005; 24 (Suppl. 1): 94—100.
4.
Burrell R.Human responses to bacterial endotoxin. Circ Shock1994; 43: 137—153.
5.
Stolley PDFever therapy: lessons from the history and efficacy of malariotherapy . In: Mackowiak PA. (ed) Fever: Basic Mechanisms and Management, 2nd edn. Philadelphia, PA: Lippincott-Raven , 1997; 331—335.
6.
Ellingson HV , Clark PFThe influence of artificial fever on mechanisms of resistance. J Immunol1942 ; 43: 65—81.
7.
Rodbard D., Rodbard HW, Rodbard S.Temperature: a critical factor determining localization and natural history of infectious, metabolic, and immunological diseases. Perspect Biol Med1980; 23: 439—474.
8.
Morgan HRImmunologic properties of an antigenic material isolated from Eberthella typhosa . J Immunol1941; 41: 161.
9.
Favorite GO, Morgan HREffects produced by the intravenous injection in man of a toxic antigenic material derived from Eberthella typhosa: clinical, hematological, chemical and serological studies. J Clin Invest1942 ; 21: 589—599.
10.
Morgan HRTolerance to the toxic action of somatic antigens of enteric bacilli . J Immunol1948: 59: 129.
11.
Neva FA, Morgan HRTolerance to the action of endotoxins of enteric bacilli in patients convalescent from typhoid and paratyphoid fevers. J Lab Clin Med1950; 35: 911—922.
12.
Heyman A., Beeson PBInfluence of various disease states upon the febrile response to intravenous injection of typhoid pyrogen. J Lab Clin Med1949; 34: 1400—1403.
13.
Beeson PBTolerance to bacterial pyrogens. I. Factors influencing its development . J Exp Med1947; 86: 29.
14.
Morgan HRResistance to the action of the endotoxins of enteric bacilli in man . J Clin Invest1948; 27: 706—709.
15.
Beeson PBTolerance to bacterial pyrogens. II. Role of the reticuloendothelial system . J Exp Med1947; 86: 39.
16.
Shwartzman G.Phenomenon of Local Tissue Reactivity. New York: Paul Hoeber, 1937.
17.
Thomas L., Good RAStudies on generalized Shwartzman reaction. General observations concerning phenomenon. J Exp Med1952; 96: 605—624.
18.
Thomas L.Mechanism involved in tissue damage by endotoxins of Gram-negative bacteria . In: Lawrence HS. (ed) Cellular and Humoral Aspects of the Hypersensitive States. New York: Hoeber-Harper, 1959; 1—667.
19.
Davis CE, Arnold K.Role of meningococcal endotoxin in meningococcal purpura. J Exp Med1974; 149: 159—171.
20.
Wolff SM, Rubenstein M., Mulholland JH, Alling DWComparison of hematologic and febrile response to endotoxin in man . Blood1965; 26: 190—201.
21.
Michie HR, Manogue KR, Spriggs DR et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med1988; 318: 1481—1486.
22.
Granowitz EV , Porat R., Gelfand JA, Wolff SM, Dinarello CAAdministration of low-dose endotoxin to healthy humans increases C5a binding to circulating neutrophils. J Infect Dis1994 ; 169: 480—482.
23.
Granowitz EV , Porat R., Orencole SF et al. Granulocyte-macrophage colony stimulating factor synthesis during experimental endotoxemia in humans . J Infect Dis1992; 166: 1204—1205.
24.
Granowitz EV , Santos AA, Poutsiaka DD et al. Production of interleukin-1 receptor antagonist during experimental endotoxemia. Lancet1991; 338: 1423—1424.
25.
Kimball HR, Melmon ML, Wolff SMEndotoxin-induced kinin production in man. Proc Soc Exp Biol Med1972; 139: 1078—1082.
26.
Greisman SE , Hornick RB, Carozza Jr FA, Woodward TE. The role of endotoxin during typhoid fever and tularemia in man. I. Acquisition of tolerance to endotoxin. J Clin Invest1963 ; 42: 1064—1075.
27.
Greisman SE , Wagner HN, Iio M., Hornick RBMechanisms of endotoxin tolerance. II. Relationship between endotoxin tolerance and reticuloendothelial system phagocytic activity in man. J Exp Med1964; 119: 241—264.
28.
Greisman SE , Hornick RB, Wagner Jr HN, Woodward WE, Woodward TEThe role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanism during infection. J Clin Invest1969; 48: 613—664.
29.
Greisman SE , Woodward WEMechanisms of endotoxin tolerance. III The refractory state during continuous intravenous infusion of endotoxin . J Exp Med1965; 121: 911—933.
30.
Hall SSA Commotion in the Blood: Life, Death and the Immune System. New York: Henry Holt, Chapters 1—5.
31.
Beebe SP, Tracy M.The treatment of experimental tumors with bacterial toxins. JAMA1907; 49: 1493—1498.
32.
Hartwell Jl , Shear Mj, Adams Jr Jr.Chemical treatment of tumors. VII. Nature of hemorrhage-producing fraction from Serratia marcescens (Bacillus prodigiosus) culture filtrate. J Natl Cancer Inst1943; 4: 107—122.
33.
Carswell EA , Old LJ, Kassel RL, Green S., Fiore N., Williamson B.An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA1975; 72: 3666—3670.
34.
Westphal O. , Luderitz O., Bister E.Uber die extraction von bacterien mit phenol/wasser . Z Naturforsch Teil B1952; 7: 148.
35.
Rudbach JA, Akiya FI, Elin RJ et al. Preparation and properties of a national reference endotoxin. J Clin Microbiol1976; 3: 21—25.
36.
Suffredini AF, Hochstein HD, McMahon FGDose-related inflammatory effects of intravenous endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J Infect Dis1999; 179: 1278—1282.
37.
Poole S., Mussett MVThe International Standard for Endotoxin: evaluation in an international collaborative study. J Biol Stand1989; 17: 161—171.
38.
Williams WV , Fullerton T., Fox JC, Enslin MB, Murray L., Jorkasky D.Asystole following endotoxin administration . J Endotoxin Res2000; 6: 303—306.
39.
van Eijk Ltgj , Pickkers P., Smits P., Bouw Mpwjm, van der Hoeven JGSevere vagal response after endotoxin administration in humans. Intensive Care Med2004; 30: 2279—2281.
40.
a. Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RLShock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med1993; 328: 1457—1460.
41.
Copeland S. , Warren HS, Lowry SF, Calvano SE, Remick D.Acute inflammatory response to endotoxin in mice and humans; Inflammation and the Host Response to Injury Investigators . Clin Diagn Lab Immunol2005; 12: 60—67.
42.
Coyle SM, Calvano SE, Lowry SFGender influences in vivo human responses to endotoxin. Shock2006; 26: 538—543.
43.
van Eijk LT , Dorresteijn MJ, Smits P., van der Hoeven JG, Netea MG, Pickkers P.Gender differences in the innate immune response and vascular reactivity following the administration of endotoxin to human volunteers. Crit Care Med2007; 35: 1464—1469.
44.
Krabbe KS, Bruunsgaard H., Hansen CM et al. Ageing is associated with a prolonged fever response in human endotoxemia. Clin Diagn Lab Immunol2001; 8: 333—338.
45.
Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med1989; 321: 280—287.
46.
van Bockel EA, Tulleken JE, Muller Kobold AC et al. Cardiac troponin I release and cytokine response during experimental human endotoxaemia . Intensive Care Med2003; 29: 1598—1600.
47.
Pleiner J., Heere-Ress E., Langenberger H. et al. Adrenoceptor hyporeactivity is responsible for Escherichia coli endotoxin-induced acute vascular dysfunction in humans. Arterioscler Thromb Vasc Biol2002; 22: 95—100.
48.
Martich GD, Parker MM, Cunnion RE, Suffredini AFEffects of ibuprofen and pentoxifylline on the cardiovascular response of normal humans to endotoxin. J Appl Physiol1992; 73: 925—931.
49.
Jellema WT, Veerman DP, De Winter RJ et al. In vivo interaction of endotoxin and recombinant bactericidal/permeability-increasing protein (rBPI23): hemodynamic effects in a human endotoxemia model . J Lab Clin Med2002; 140: 228—235.
50.
de Winter RJ , von der Mohlen MA, van Lieshout H.Recombinant endotoxin-binding protein (rBPI 23) attenuates endotoxin-induced circulatory changes in humans. J Inflamm1995; 45: 193—206.
51.
Suffredini AF, Shelhamer JH, Neumann RD, Brenner M., Baltaro RJ, Parrillo JEPulmonary and oxygen transport effects of intravenously administered endotoxin in normal humans. Am Rev Respir Dis1992; 145: 1398—1403.
52.
a. Boujooukos AJ, Martich GD, Supinski E., Suffredini AFCompartmentalization of the acute cytokine response in humans after intravenous endotoxin administration . J Appl Physiol1993; 74: 3027—3033.
53.
Smith PD, Suffredini AF, Allen JB, Wahl LM, Parrillo JE, Wahl SMEndotoxin administration to humans primes alveolar macrophages for increased production of inflammatory mediators. J Clin Immunol1994; 14: 141—148.
54.
Pollard V., Prough DS, Deyo DJ et al. Cerebral blood flow during experimental endotoxemia in volunteers . Crit Care Med1997; 25: 1700—1706.
55.
Pollmacher T., Mullington J., Korth C. et al. Diurnal variations in the human host response to endotoxin. J Infect Dis1996; 174: 1040—1045.
56.
Krabbe KS, Reichenberg A., Yirmiya R., Smed A., Pedersen BK, Bruunsgaard H.Low-dose endotoxemia and human neuropsychological functions. Brain Behav Immun2005; 19: 453—460.
57.
Reichenberg A., Yirmiya R., Schuld A. et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry2001; 58: 445—452.
58.
Catania A., Suffredini AF, Lipton JMEndotoxin causes release of alpha-melanocyte-stimulating hormone in normal human subjects. Neuroimmunomodulation1995 ; 2: 258—262.
59.
Jorgensen VL , Ibsen M., Andressen L., Schulzke JD, Perner A.Effects of endotoxaemia on markers of permeability, metabolism and inflammation in the large bowel of healthy subjects. Acta Anaesthesiol Scand207; 51: 1085—1092.
60.
Pastor RO, LopezSan Roman A, Albeniz Arbizu E, de la Hera Martinez A, Ripoli Sevillano E, Albillos Martinez A. Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis2007; 13: 269—277.
61.
Sharma R., Tepas 3rd JJ, Hudak ML et al. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. J Pediatr Surg2007; 42: 454—461.
62.
Heemskerk S. , Pickkers P., Bouw Mpwjm et al. Upregulation of renal inducible nitric oxide synthase during human endotoxemia and sepsis is associated with proximal tubule injury. Clin J Am Soc Nephrol2006; 1: 853—862.
63.
Schuld A., Mullington J., Friess E. et al. Changes in dehydroepiandrosterone (DHEA) and DHEA-sulfate plasma levels during experimental endotoxinemia in healthy volunteers. J Clin Endocrinol Metab2000; 85: 4624—4629.
64.
Calvano SE, Barber AE, Hawes AS, de Riesthal HF, Coyle SM, Lowry SFEffect of combined cortisol-endotoxin administration on peripheral blood leukocyte counts and phenotype in normal humans. Arch Surg1992; 127: 181—186.
65.
van der Poll T., Coyle SM, Barbosa K., Braxton CC, Lowry SFEpinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest1996; 97: 713—719.
66.
van der Poll T., Barber AE, Coyle SM, Lowry SFHypercortisolemia increases plasma interleukin-10 concentrations during human endotoxemia — A clinical research study . J Clin Endocrinol Metab1996; 81: 3604—3606.
67.
de Kruif MD , Lemaire LC, Giebelen IA et al. Prednisolone dose-dependently influences inflammation and coagulation during human endotoxemia . J Immunol2007; 178: 1845—1851.
68.
van der Poll T., Van Zee KJ, Endert E. et al. Interleukin-1 receptor blockade does not affect endotoxin-induced changes in plasma thyroid hormone and thyrotropin concentrations in man. J Clin Endocrinol Metab1995; 80: 1341—1346.
69.
Fong Y., Marano MA, Mldawer LL et al. The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest1990 ; 85: 1896—1904.
70.
Agwunobi AO , Reid C., Maycock P., Little RA, Carlson GLInsulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab2000; 85: 3770—3778.
71.
Bornstein SR , Preas HL, Chrousos GP, Suffredini AFCirculating leptin levels during acute experimental endotoxemia and antiinflammatory therapy in humans. J Infect Dis1998; 178: 887—890.
72.
Keller P., Moller K., Krabbe KS, Pedersen BKCirculating adiponectin levels during human endotoxaemia. Clin Exp Immunol2003; 134: 107—110.
73.
Vesali RF, Klaude M., Rooyackers O., Wernerman J.Amino acid metabolism in leg muscle after an endotoxin injection in healthy volunteers. Am J Physiol2005; 288: E360—E364.
74.
Kemna E., Pickkers P., Nemeth E., van der Hoeven H., Swinkels D.Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood2005; 106: 1864—1866.
75.
Gaetke LM, McClain CJ, Talwalkar RT, Shedlofsky SIEffects of endotoxin on zinc metabolism in human volunteers. Am J Physiol1997; 272: E952—E956.
76.
Hesse DG, Tracey KJ, Fong Y. et al. Cytokine appearance in human endotoxemia and primate bacteremia . Surg Gynecol Obstet1988; 166: 147—153.
77.
Cross AS, Opal SM, Sadoff JC, Gemski P.Choice of bacteria in animal models of sepsis. Infect Immun1993; 61: 2741—2747.
78.
Cannon JG, Tompkins RG, Gelfand JA et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis1990; 161: 79—84.
79.
Meisner M., Muller V., Khakpour Z., Toegel E., Redl H.Induction of procalcitonin and proinflammatroy cytokines in an anhepatic baboon endotoxin shock model. Shock2003; 19: 187—190.
80.
Koopmans R. , Hoek FJ, van Deventer SJ, van der Poll T.Model for whole body production of tumour necrosis factor-alpha in experimental endotoxaemia in healthy subjects. Clin Sci (Lond)1994 ; 87: 459—465.
81.
van der Poll T., Calvano SE, Kumar A. et al. Endotoxin induces downregulation of tumor necrosis factor receptors on circulating monocytes and granulocytes in humans. Blood1995; 86: 2754—2759.
82.
Jansen J., van der Poll T., Levi M. et al. Inhibition of the release of soluble tumor necrosis factor receptors in experimental endotoxemia by an anti-tumor necrosis factor-alpha antibody . J Clin Immunol1995; 15: 45—50.
83.
van der Poll T., van Deventer SJ, ten Cate H., Levi M., ten Cate JWTumor necrosis factor is involved in the appearance of interleukin-1 receptor antagonist in endotoxemiaJ Infect Dis1994; 169: 665—667.
84.
van der Poll T., van Deventer SJ, Buller HR, Sturk A., ten Cate JWComparison of the early dynamics of systemic prostacyclin release after administration of tumor necrosis factor and endotoxin to healthy humans. J Infect Dis1991; 164: 599—601.
85.
von der Mohlen MA, van der Poll T., Jansen J., Levi M., van Deventer SJRelease of bactericidal/permeability-increasing protein in experimental endotoxemia and clinical sepsis. Role of tumor necrosis factor. J Immunol1996; 156: 4969—4973.
86.
van der Poll T., Coyle SM, Levi M. et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood1997; 89: 3727—3734.
87.
Fong Y., Moldawer LL, Marano M. et al. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol1989; 142: 2321—2324.
88.
Panacek EA, Marshall JC, Albertson TE et al. Monoclonal Anti-TNF: a Randomized Controlled Sepsis Study Investigators. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med2004; 32: 2173—2182.
89.
Reinhart K. , Menges T., Gardlund B. et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory responses during severe sepsis: The RAMSES Study. Crit Care Med2001; 29: 765—769.
90.
Fisher Jr CJ , Opal SM, Dhainaut JF et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med1993; 21: 318—327.
91.
Marsik C., Halama T., Cardona F., Schlifke I., Mittermayer F., Jilma B.Endotoxemia enhances expression of the signaling receptor (GP130) on protein and molecular level. Clin Immunol2005; 114: 293—298.
92.
Pajkrt D., Manten A., van der Poll T. et al. Modulation of cytokine release and neutrophil function by granulocyte colony-stimulating factor during endotoxemia in humans. Blood1997; 90: 1415—1424.
93.
Dekkers P., Juffermans N., Hove T. et al. Granulocyte colonystimulating factor receptors on granulocytes are down-regulated after endotoxin administration to healthy human. J Infect Dis2000; 181: 2067—2070.
94.
Endler G., Marsik C., Joukhadar C. et al. The interleukin-6 G(—174)C promoter polymorphism does not determine plasma interleukin-6 concentrations in experimental endotoxemia in humans. Clin Chem2004; 50: 195—200.
95.
Kovar FM, Marsik C., Jilma B. et al. The fibrinogen —148 C/T polymorphism influences inflammatory response in experimental endotoxemia in vivo. Thromb Res2007; 120: 727—731.
96.
Kovar FM, Marski C., Cvitko T., Wagner OF, Jilma B., Endler G.The tumor necrosis factor alpha —308 G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia. Shock2007; 27: 238—241.
97.
Granowitz EV , Santos AA, Poutsiaka DD et al. Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet1991; 338: 1423—1424.
98.
Weijer S., Lauw FN, Branger J., van den Blink B., van der Poll T.Diminished interferon-gamma production and responsiveness after endotoxin administration to healthy humans. J Infect Dis2002; 186: 1748—1753.
99.
Cavaillon JM , Munoz C., Fitting C., Misset B., Carlet J.Circulating cytokines: the tip of the iceberg?Circ Shock1992; 38: 145—152.
100.
Prabhakar U. , Conway TM, Murdock P. et al. Correlation of protein and gene expression profiles of inflammatory proteins after endotoxin challenge in human subjects . DNA Cell Biol2005; 24: 410—431.
101.
Munoz C., Misset B., Fitting C., Bleriot JP, Carlet J., Cavaillon JMDissociation between plasma and monocyte-associated cytokines during sepsis . Eur J Immunol1991; 21: 2177—2184.
102.
Sprong T., Pickkers P., Geurts-Moespot A. et al. Macrophage migration inhibitory factor (MIF) in meningococcal septic shock and experimental human endotoxemia. Shock2007; 27: 482—487.
103.
Olszyna DP , Pajkrt D., Lauw FN, van Deventer SJ, van der Poll T.Interleukin 10 inhibits the release of CC chemokines during human endotoxemia. J Infect Dis2000; 181: 613—620.
104.
Pajkrt D., Camoglio L., Tiel-van Buul MC et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration . J Immunol1997; 158: 3971—3977.
105.
Lauw FN, Pajkrt D., Hack CE, Kurimoto M., van Deventer SJ, van der Poll T.Proinflammatory effects of IL-10 during human endotoxemia. J Immunol2000; 165: 2783—2789.
106.
Olszyna DP , Prins JM, Dekkers PE et al. Sequential measurements of chemokines in urosepsis and experimental endotoxemia. J Clin Immunol1999; 19: 399—405.
107.
Martich GD , Danner RL, Ceska M., Suffredini AFDetection of interleukin-8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of anti-inflammatory agents. J Exp Med1991; 173: 1021—1024.
108.
Heesen M., Renckens R., de Vos AF, Kunz D., van der Poll T.Human endotoxemia induces down-regulation of monocyte CC chemokine receptor 2. Clin Vaccine Immunol2006; 13: 156—159.
Calvano JE , Bowers DJ, Coyle SM et al. Response to systemic endotoxemia among humans bearing polymorphisms of the Toll-like receptor 4 (hTLR4). Clin Immunol2006; 121: 186—190.
111.
Knapp S., Gibot S., de Vos A., Versteeg HH, Colonna M., van der Poll T.Expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J Immunol2004; 173: 7131—7134.
112.
van der Meer W., Pickkers P., Scott CS, van der Hoeven JG, Gunnewiek J.Hematological indices, inflammatory markers and neutrophil CD64 expression: comparative trends during experimental human endotoxemia. J Endotoxin Res2007; 13: 94—100.
113.
Dekkers PE , Juffermans NP, ten Hove T., de Jonge E., van Deventer SJ, van der Poll T.Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans. J Infect Dis2000; 181: 1055—1061.
114.
Calvano SE , Thompson WA, Marra MN et al. Changes in polymorphonuclear leukocyte surface and plasma bactericidal/permeability-increasing protein and plasma lipopolysaccharide binding protein during endotoxemia or sepsis . Arch Surg1994; 129: 220—226.
115.
Dekkers PE , ten Hove T., te Velde AA, van Deventer SJ, van Der Poll T.Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia . Infect Immun2000; 68: 2156—2160.
116.
Florquin S. , van den Berg JG, Olszyna DP et al. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int2001; 59: 2054—2061.
117.
Ostrowski SR, Plomgaard P., Fischer CP et al. Interleukin-6 infusion during human endotoxaemia inhibits in vitro release of the urokinase receptor from peripheral blood mononuclear cells. Scand J Immunol2005 ; 61: 197—206.
118.
Wilson M., Blum R., Dandona P., Mousa S.Effects in humans of intravenously administered endotoxin on soluble cell-adhesion molecules and inflammatory markers: a model of human diseases . Clin Exp Pharmacol Physiol2001; 28: 376—380.
119.
Soop A., Albert J., Weitzberg E., Bengtsson A., Lundberg JO, Sollevi A.Complement activation, endothelin-1 and neuropeptide Y in relation to the cardiovascular response to endotoxin-induced systemic inflammation in healthy volunteers. Acta Anaesthesiol Scand2004; 48: 74—81.
120.
van Eijk LT , Pickkers P., Smits P., van den Broek W., Bouw MP, van der Hoeven JGMicrovascular permeability during experimental human endotoxemia: an open intervention study . Crit Care2005; 9: R157—R164.
121.
van Eijk LT , Nooteboom A., Hendriks T. et al. Plasma obtained during human endotoxemia increases endothelial albumin permeability in vitro . Shock2006; 25: 358—362.
122.
Mayr FB, Spiel AO, Leitner JM, Firbas C., Sieghart W., Jilma B.Effects of low dose endotoxemia on endothelial progenitor cells in humans . Atherosclerosis2007; 195: e202—e206.
123.
Krabbe KS, Bruunsgaard H., Qvist J. et al. Activated T lymphocytes disappear from circulation during endotoxemia in humans. Clin Diagn Lab Immunol2002; 9: 731—735.
124.
Lauw FN, Simpson AJ, Hack CE et al. Soluble granzymes are released during human endotoxemia and in patients with severe infection due to Gram-negative bacteria. J Infect Dis2000; 182: 206—213.
125.
Pugin J., Widmer MC, Kossodo S., Liang CM, Preas 2nd HL, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators . Am J Respir Cell Mol Biol1999; 20: 458—464.
126.
Albert J., Radomski A., Soop A., Sollevi A., Frostell C., Radomski MWDifferential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers. Acta Anaesthesiol Scand2003; 47: 407—410.
127.
Grobmyer SR , Barie PS, Nathan CF et al. Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med2000; 28: 1276—1282.
128.
van den Blink B., Branger J., Weijer S., Deventer SH, van der Poll T., Peppelenbosch MPHuman endotoxemia activates p38 MAP kinase and p42/44 MAP kinase, but not c-Jun N-terminal kinase . Mol Med2001; 7: 755—760.
129.
Branger J., van den Blink B., Weijer S. et al. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol2002; 168: 4070—4077.
130.
Fijen JW, Zijlstra JG, De Boer P. et al. Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol2001; 124: 16—20.
131.
Dekkers PE, Lauw FN, ten Hove T. et al. The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia . Blood1999; 94: 2252—2258.
132.
Verbon A., Dekkers PE, ten Hove T. et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol2001; 166: 3599—3605.
133.
Spek CA, Verbon A., Aberson H. et al. Treatment with an anti-CD14 monoclonal antibody delays and inhibits lipopolysaccharide-induced gene expression in humans in vivo. J Clin Immunol2003; 23: 132—140.
134.
Pajkrt D., Doran JE, Koster F. et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med1996; 184: 1601—1618.
135.
Erikstrup C., Ullum H., Pedersen BKShort-term simvastatin treatment has no effect on plasma cytokine response in a human in vivo model of low-grade inflammation . Clin Exp Immunol2006; 144: 94—100.
136.
van der Poll T., Braxton CC, Coyle SM et al. Effect of hypertriglyceridemia on endotoxin responsiveness in humans. Infect Immun1995 ; 63: 3396—3400.
137.
Li N., Soop A., Sollevi A., Hjemdahl P.Multi-cellular activation in vivo by endotoxin in humans — limited protection by adenosine infusion. Thromb Haemost2000 ; 84: 381—387.
138.
Lemaire LC , de Kruif MD, Giebelen IA, Levi M., van der Poll T., Heesen M.Dobutamine does not influence inflammatory pathways during human endotoxemia. Crit Care Med2006; 34: 1365—1371.
139.
Graninger M., Marsik C., Dukic T., Wagner OF, Blann AD, Jilma B.Enalapril does not alter adhesion molecule levels in human endotoxemia. Shock2003; 19: 448—451.
140.
Soop A., Albert J., Weitzberg E., Bengtsson A., Nilsson CG, Sollevi A.Nicotinamide does not influence cytokines or exhaled NO in human experimental endotoxaemia. Clin Exp Immunol2004; 135: 114—118.
141.
Spinas GA, Bloesch D., Keller U., Zimmerli W., Cammisuli S.Pretreatment with ibuprofen augments circulating tumor necrosis factor-alpha, interleukin-6, and elastase during acute endotoxinemia. J Infect Dis1991; 163: 89—95.
142.
Preas 2nd HL, Nylen ES, Snider RH et al. Effects of antiinflammatory agents on serum levels of calcitonin precursors during human experimental endotoxemia . J Infect Dis2001; 184: 373—376.
143.
Granowitz EV, Porat R., Mier JW et al. Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood. 1993; 82: 2985—2990.
144.
Van Zee KJ , Coyle SM, Calvano SE et al. Influence of IL-1 receptor blockade on the human response to endotoxemia. J Immunol1995; 154: 1499—1507.
145.
Santos AA, Scheltinga MR, Lynch E. et al. Elaboration of interleukin 1-receptor antagonist is not attenuated by glucocorticoids after endotoxemia. Arch Surg1993; 128: 138—143, discussion 143—144.
146.
Astiz ME, Rackow EC, Still JG et al. Pretreatment of normal humans with monophosphoryl lipid A induces tolerance to endotoxin: A prospective, double-blind, randomized controlled trial. Crit Care Med1995; 23: 9.
147.
Bunnell E. , Lynn M., Habet K. et al. A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia . Crit Care Med2000; 28: 2713—2720.
148.
Lynn M., Rossignol DP, Wheeler JL et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis2003; 187: 631—639.
149.
Rossignol DP, Lynn M.Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res2002; 8: 483—488.
150.
Lynn M., Wong YN, Wheeler JL et al. Extended in vivo pharmacodynamic activity of E5564 (alpha-D-glucopyranose) in normal volunteers with experimental endotoxemia. J Pharmacol Exp Ther2004; 308: 175—181.
151.
Lynn M., Rossignol DP, Wheeler JL et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis2003; 187: 631—639.
152.
Franco RF, de Jonge E., Dekkers PE et al. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation. Blood2000; 96: 554—559.
153.
van der Poll T., Levi M., Braxton CC et al. Parenteral nutrition facilitates activation of coagulation but not of fibrinolysis during human endotoxemia. J Infect Dis1998; 177: 793—795.
154.
Reitsma PH , Branger J, VanDen Blink B, Weijer S, Van Der Poll T, Meijers JC. Procoagulant protein levels are differentially increased during human endotoxemia. J Thromb Haemost2003; 1: 1019—1023.
155.
Minnema MC , Pajkrt D., Wuillemin WA et al. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood1998; 92: 3294—3301.
156.
Suffredini AF, Harpel PC, Parrillo JEPromotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects . N Engl J Med1989; 320: 1165—1172.
157.
Reiter R., Derhaschnig U., Spiel A. et al. Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost2003 ; 90: 898—903.
158.
Jilma B., Blann A., Pernerstorfer T. et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med1999; 159: 857—863.
159.
Borchiellini A., Fijnvandraat K., ten Cate JW et al. Quantitative analysis of von Willebrand factor propeptide release in vivo: effect of experimental endotoxemia and administration of 1-deamino-8-D-arginine vasopressin in humans . Blood1996; 88: 2951—2958.
160.
Pernerstorfer T., Schmid R., Bieglmayer C., Eichler HG, Kapiotis S., Jilma B.Acetaminophen has greater antipyretic efficacy than aspirin in endotoxemia: a randomized, double-blind, placebo-controlled trial. Clin Pharmacol Ther1999; 66: 51—57.
161.
Pernerstorfer T., Hollenstein U., Hansen J. et al. Heparin blunts endotoxin-induced coagulation activation. Circulation1999; 100: 2485—2490.
162.
Derhaschnig U., Pernerstorfer T., Knechtelsdorfer M., Hollenstein U., Panzer S., Jilma B.Evaluation of antiinflammatory and antiadhesive effects of heparins in human endotoxemia. Crit Care Med2003; 31: 1108—1112.
163.
van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A.Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways . Blood1990; 76: 2520—2526.
164.
de Jonge E. , Dekkers PE, Creasey AA et al. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia . Blood2000 ; 95: 1124—1129.
165.
de Jonge E., Dekkers P., Creasey A. et al. Tissue factor pathway inhibitor does not influence inflammatory pathways during human endotoxemia. J Infect Dis2001; 183: 1815—1818.
166.
Renckens R., Weijer S., de Vos AF et al. Inhibition of plasmin activity by tranexamic acid does not influence inflammatory pathways during human endotoxemia. Arterioscler Thromb Vasc Biol2004; 24: 483—488.
167.
Branger J. , van den Blink B., Weijer S. et al. Inhibition of coagulation, fibrinolysis, and endothelial cell activation by a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Blood2003; 101: 4446—4448.
168.
Verbon A., Meijers JC, Spek CA et al. Effects of IC14, an anti-CD14 antibody, on coagulation and fibrinolysis during low-grade endotoxemia in humans. J Infect Dis2003; 187: 55—61.
169.
Pajkrt D., Lerch PG, van der Poll T. et al. Differential effects of reconstituted high-density lipoprotein on coagulation, fibrinolysis and platelet activation during human endotoxemia . Thromb Haemost1997; 77: 303—307.
170.
van der Poll T., Levi M., Dentener M. et al. Epinephrine exerts anticoagulant effects during human endotoxemia. J Exp Med1997; 185: 1143—1148.
171.
von der Mohlen MA, van Deventer SJ et al. Inhibition of endotoxin-induced activation of the coagulation and fibrinolytic pathways using a recombinant endotoxin-binding protein (rBPI23). Blood1995; 85: 3437—3443.
172.
de Pont AC , Moons AH, de Jonge E. et al. Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia. J Thromb Haemost2004; 2: 65—70.
173.
Pajkrt D., van der Poll T., Levi M. et al. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood1997; 89: 2701—2705.
174.
Jilma-Stohlawetz P., Folman CC, von dem Borne AE et al. Effects of anticoagulation on thrombopoietin release during endotoxemia. J Lab Clin Med2001; 137: 64—69.
175.
Derhaschnig U., Pachinger C., Schweeger-Exeli I., Marsik C., Jilma B.Blockade of GPIIb/IIIa by eptifibatide and tirofiban does not alter tissue factor induced thrombin generation in human endotoxemia. Thromb Haemost2003; 90: 1054—1060.
176.
Kalil AC, Coyle SM, Um JY et al. Effects of drotrecogin alfa (activated) in human endotoxemia . Shock2004; 21: 222—229.
177.
Derhaschnig U., Reiter R., Knobl P., Baumgartner M., Keen P., Jilma B.Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia . Blood2003; 102: 2093—2098.
178.
Munford REDetoxifying endotoxin: time, place and person . J Endotoxin Res2005; 11: 69—84.
179.
Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JEEndotoxemia in human septic shock. Chest1991 ; 99: 169—175.
180.
Senterfitt VC, Shands Jr JW. Salmonellosis in mice infected with Mycobacterium tuberculosis BCG. I. Role of endotoxin in infection. J Bacteriol1968; 96: 287—292.
